NCT00107497 (FAST) is a NA clinical trial of Radiation therapy in Breast Cancer, sponsored by Institute of Cancer Research, United Kingdom.

Who is sponsoring NCT00107497?

NCT00107497 is sponsored by Institute of Cancer Research, United Kingdom.

What drugs are being tested in NCT00107497?

Interventions in NCT00107497: Radiation therapy.

What condition does NCT00107497 study?

NCT00107497 studies Breast Cancer.

Is NCT00107497 still recruiting?

NCT00107497 is currently completed. Last updated 27 February 2019.

Last reviewed 2019-02-27 · How we verify

NCT00107497: FAST

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Radiation Therapy in Treating Women With Localized Breast Cancer

Completed NA Last updated 27 February 2019

What this trial tests

NA trial testing Radiation therapy in Breast Cancer in 917 participants. Completed in 9 March 2017.

Timeline

5 October 2004

Primary endpoint
9 March 2007

9 March 2017

Quick facts

Lead sponsor	Institute of Cancer Research, United Kingdom
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	917
Start date	5 October 2004
Primary completion	9 March 2007
Estimated completion	9 March 2017
Sites	19 locations across United Kingdom

Drugs / interventions tested

Radiation therapy — full drug profile →

Conditions studied

Breast Cancer — all drugs for Breast Cancer →

Sponsor

Institute of Cancer Research, United Kingdom

Who can join

Adults 50 to 120, female only, with Breast Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Giving radiation therapy in different ways and giving it after surgery may kill any tumor cells that remain after surgery. PURPOSE: This randomized clinical trial is studying radiation therapy to see how well it works in treating women with localized breast cancer.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Ten-Year Results of FAST: A Randomized Controlled Trial of 5-Fraction Whole-Breast Radiotherapy for Early Breast Cancer.
Brunt AM, Haviland JS, Sydenham M, Agrawal RK, et al · · 2020 · cited 198× · PMID 32663119 · DOI 10.1200/jco.19.02750

Verify or expand the search:

Other trials of Radiation therapy

Trials testing the same drug.

NCT06990061 — Radiotherapy for BCG-unresponsive Non-muscle-invasive Carcinoma in Situ (CIS) Bladder Cancer: an Open-label, Single-arm, · NA · not yet recruiting
NCT06831526 — Neoadjuvant Chemoradiotherapy With or Without Concurrent Azeliragon in Patients With Newly Diagnosed Glioblastoma · EARLY_PHASE1 · recruiting
NCT05608369 — Vorinostat in Combination With Chemoradiation in Locally Advanced HPV Negative HNSCC · Phase 2 · withdrawn
NCT06702033 — The Minimalist Trial-2 · Phase 2 · recruiting
NCT06583070 — SABR Combined With Targeted Therapy and Anti-PD-1 for Recurrent or Metastatic Renal Cancer · recruiting

Other recruiting trials for Breast Cancer

Currently open trials in the same condition.

NCT06148038 — CBD for Breast Cancer Primary Tumors · Phase 1 · recruiting
NCT07405801 — A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus R · Phase 2 · recruiting
NCT07285993 — Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET · Phase 2 · recruiting
NCT07510698 — Same-Day Awake Mastectomy With Immediate Breast Reconstruction for Patients With Breast Cancer · NA · recruiting
NCT06768931 — Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer · Phase 2 · recruiting

Other Institute of Cancer Research, United Kingdom trials

Trials by the same sponsor.

NCT06396754 — Deployment and Clinical Evaluation of an AI-powered Digital Oncology Biomarker Tool to guidE Treatment in TNBC · not yet recruiting
NCT07391215 — 5G-PEARL: Paxalisib in Malignant Brain Tumours · Phase 1, PHASE2 · recruiting
NCT07098819 — The eValuation of Sources of vIBRAtioN for Vibrational Shear Wave elasTography · not yet recruiting
NCT06636526 — The i4i PRODICT® Study: Evaluation of the i4i PRODICT® Test in Different Ethnic Groups (The i4i PRODICT® Study). · recruiting
NCT06630260 — 5G-RUBY: Avutometinib and Defactinib in Malignant Brain Tumours · Phase 1, PHASE2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00107497 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Institute of Cancer Research, United Kingdom
Last refreshed: 27 February 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00107497.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing